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1. Introduction 
MYCN is a member of the MYC family of oncogenes, which also includes c-MYC and MYCL. 
Despite knowing about the existence of MYCN for nearly thirty years, the majority of 
functional studies involving MYC family members have focused on c-MYC due to the 
limited expression profile of MYCN in human cancers, and also in part due to the existence 
of highly conserved functional domains between c-MYC and MYCN [1]. MYCN is normally 
expressed during embryonal development and orchestrates cell proliferation and 
differentiation in the developing peripheral neural crest [2]. However, the deregulated 
expression of MYCN has been shown to contribute to tumorigenesis and neuronal 
transformation [3]. Thus, MYCN represents a highly desirable therapeutic target. Previous 
studies have shown that downregulating MYCN expression, via antisense oligonucleotides, 
resulted in lower tumour incidence and decreased tumour mass in a murine neuroblastoma 
tumour model [4]. However, to date, no molecularly targeted therapies have been 
developed that are able to mimic this response in the clinic, and further studies are required 
to help elucidate the mechanisms that drive MYCN tumour formation and progression. 
2. The MYC family and the discovery of MYCN 
The eventual discovery of MYC oncogenes arose from early pioneering work on the Rous 
sarcoma virus (RSV), a transforming retrovirus able to cause sarcomas in infected chicken 
cells. Using the information provided by RSV, hybridisation studies were performed on a 
specific group of avian tumours involving a retrovirus responsible for inducing myeloid 
leukaemia. This led to the identification of a sequence that was named v-gag-myc, or v-myc 
for myelocytomatosis (the leukaemia that is induced following the transduction of avian 
cells with this virus) and supported the idea that viral integration into a host genome could 
activate a nearby host oncogene [5, 6]. As it transpired, the human homologue of v-myc, 
termed c-MYC (cellular-MYC) was the first cellular oncogene whose overexpression was 
 Oncogene and Cancer – From Bench to Clinic 438 
shown to be activated through retroviral insertional mutagenesis [7]. Deregulated 
expression of c-MYC has since been implicated in a range of cancers, and allowed the 
discovery of other important MYC family members including MYCN and MYCL. 
Neuroblastoma is the most common extracranial solid tumour of early childhood and 
accounts for approximately 15% of all cancer related deaths in children. Aggressive drug 
refractory neuroblastoma cells have been frequently observed to contain genomic 
aberrations referred to as double-minute chromatin bodies and homogeneously staining 
regions. Both of these types of aberrations were found to contain multiple copies or 
amplification of specific genes, and in particular, the critical gene within these regions was 
later identified to be the c-MYC-related oncogene, MYCN, so-called because of its 
identification in neuroblastoma cells [8]. Amplification of the MYCN oncogene has also been 
demonstrated in retinoblastoma, glioblastoma, medulloblastoma, astrocytoma and small cell 
lung cancer cells [9]. In addition, another member of the MYC-oncogene family, MYCL, was 
identified in small cell lung cancer (SCLC), and demonstrated homology to a small region of 
both c-MYC and MYCN. Gene mapping studies assigned MYCL to human chromosome 
region 1p32, a location that is distinct from that of either c-MYC or MYCN (regions 8q24 and 
2p24 respectively) but is also associated with cytogenetic abnormalities in certain human 
tumours such as thyroid cancer and lung cancer [10, 11]. MYCL was found to be amplified 
in some SCLC cells [12]. In mammals, a fourth member of the MYC family, s-Myc has been 
identified, however only c-MYC, MYCN and MYCL have been implicated in the 
tumorigenesis of specific human cancers [13].  
All three tumour-associated MYC genes have the same characteristic three-exon structure 
with the major polypeptide open reading frame residing in the second and third exons. The 
first exon is not conserved between the genes, but rather possesses regulatory functions, 
whereas the two coding exons produce highly homologous sections of amino acids 
interspersed with areas of diminished conservation, leading to the suggestion that 
individual MYC polypeptides have discrete, independent, functional domains [14]. In 
tumour biology, many cancers have been shown to exhibit increased levels of MYC protein 
in tumour tissue relative to the surrounding normal tissues, and this has been shown to 
contribute to the aggressiveness of the tumour [15]. Importantly, the MYC family of proteins 
share functionally similar roles, acting as transcription factors to drive cellular proliferation 
and vasculogenesis, promote metastasis and genomic instability, as well as inhibit cell 
differentiation and reduce cell adhesion [13, 16]. However, recent findings have also raised 
the possibility of transcriptionally-independent functions of the MYC proteins [17]. 
3. The functional activity of MYCN 
MYC proteins are well established as nuclear phosphoproteins that act as regulators of 
transcription, and can both activate and repress the expression of its target genes  [16]. MYCN 
encodes a 60kDa protein that has affinity for and binds to DNA, and is phosphorylated by 
casein kinase II [18, 19]. Phosphorylation is important for the transforming abilities of MYC 
family members and also for the regulation of MYC protein stability and activity [20]. The 
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affinity of MYCN protein for DNA relies on the presence of certain motifs, comprising a basic 
DNA binding region, an α-helical protein-protein interaction domain or helix-loop-helix 
(HLH), and a leucine zipper motif (Zip) encompassing the bHLH-Zip domain at the carboxy 
or C-terminus of the protein [9]. The mechanism that mediates the DNA-binding capacity of 
MYC proteins was confirmed via the identification of MAX, also a bHLH-Zip protein [21]. 
MYCN and MAX (Figure 1) interact to form a complex that binds to DNA in a sequence 
specific manner [22]. MYCN binds to MAX protein via its bHLH-LZ region. Several other 
proteins have also been shown to interact with the C-terminus of MYCN, including YY-1, AP-
2, TFII-I and BRCA1 [23], or with the central region of MYCN such as NMi [24], all of which 
are associated with MYCN’s function as a transcriptional regulator. 
 
Figure 1. Domains of the MYCN and MAX proteins. The N-terminus of MYCN has three elements, 
known as MYC homology boxes I-III, which are highly conserved in MYC proteins. The C-terminus 
contains the basic-region/helix-loop-helix/leucine-zipper that is responsible for interaction with the 
MAX protein. 
The amino or N-terminus of MYCN acts as a transactivation domain that contains two 
highly conserved regions called Myc Homology Boxes I and II (MBI and MBII) [1]. This 
region has been shown to bind to nuclear cofactors, including TRRAP, p107, BIN1, MM-1, 
AMY-1, PAM, α-Tubulin, TIP48 and TIP49, to assist the targeting of protein to specific gene 
promoters [23, 25]. Another protein YAF2, has been demonstrated to bind to the central 
region of MYCN to further stimulate transcription upon MYCN-MAX transactivation [26]. 
All of these interacting proteins are a part of a transcription factor complex by which target 
genes are activated. Myc Homology Box III (MBIII) is conserved only within c-MYC and 
MYCN, but not MYCL, and is necessary for cellular transformation [27]. A fourth Myc 
Homology Box (MBIV) is also necessary for MYC transforming activity [28]. 
Recent studies have provided evidence of a function of MYCN that is independent from its 
role as a classical transcription factor. MYCN was shown to remodel large domains of 
euchromatin, regions of lightly packaged chromatin that contain active, functioning genes, 
by regulating histone acetylation [29, 30]. Two possibilities have been suggested for this role. 
The first is that MYCN maintains the activity of euchromatin, whilst the second is that 
MYCN maintains euchromatin at remote sites to act as an enhancer and regulator of genes 
at a distance. Novel functions of other MYC proteins have been identified through 
mutational analyses that have uncoupled the transforming ability of c-MYC from its role as 
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a transcription factor [28, 31]. c-MYC was found to increase the translation of specific 
mRNAs by promoting the methylation of the 5’ mRNA guanine “cap”, including mRNAs 
encoding cyclin T1 and CDK9 [31]. A role for c-MYC has also been described in the initiation 
of DNA replication by binding to various components of the pre-replicative complex and 
localising to early sites of DNA replication [32]. These observations suggest that c-MYC may 
play a role in controlling initiation of the S phase of the cell cycle and contribute to 
replicative stress and genomic instability, to further accelerate tumorigenesis [17]. Even 
though the evidence has yet to be provided, given the high level of homology between c-
MYC and MYCN, the described transcription-independent roles of c-MYC suggest similar 
roles will be identified for MYCN in contributing to tumour cell biology. 
4. MYCN as a transcriptional activator  
As indicated above, MYCN heterodimerises with MAX and binds with high affinity to a 
CACA/GTG E-box sequence found upstream of promoter target sequences [13]. The MYCN-
MAX heterodimer activates transcription via several mechanisms. TRRAP (or 
TRansactivation/tRansformation Associated Protein) binds to the N-terminal region of 
MYCN and is essential for MYCN transformation. Through TRRAP, MYCN recruits histone 
acetylation (HAT) complexes to chromatin, including the 1.8 megaDalton SAGA complex 
(SPT/ADA/GCN5/Acetyltransferase) [33]. Histone acetylation is associated with gene 
activation by chromatin modification influencing histone-DNA and histone-histone contact 
[34]. TRRAP is involved with another HAT complex, TIP60, an H2A/H4 acetylase [35]. 
Interestingly, in vivo acetylation of histone H4 is highly associated with MYC target gene 
activation [36]. Two other proteins, TIP48 and TIP49 that are found in the TIP60 complex 
also bind to the N-terminus of MYCN [25].  Both proteins are highly conserved hexameric 
ATPases that are involved in chromatin remodelling involving the movement or 
displacement of nucleosomes, as opposed to chromatin modification [37]. 
The MYC family represents a particularly unusual set of transcription factors in that they 
can bind to and regulate approximately 10-15% of the entire genome [14]. Some MYCN 
target genes have been shown to be activated independently of TRRAP and HAT 
complexes. Investigation into HAT independent activation has revealed the involvement of 
RNA polymerase II at the promoter regions of target genes. c-MYC protein binding has been 
shown to stimulate the clearance of RNA polymerase II from the promoter region to allow 
for efficient transcription elongation by the RNA pol II kinases, TFIIH and positive 
transcription elongation factor b (PTEFb) [38]. c-MYC also regulates RNA pol II promoter 
clearance by controlling the expression of RNA pol II kinases via mRNA cap methylation, 
polysome loading, and the rate of translation [31]. 
5. MYCN as a transcriptional repressor 
Most studies have focused on the role of MYC proteins as transcriptional activators. 
However, cells transformed by constitutive expression of c-MYC are characterised by the 
loss of expression of numerous genes such as those involved in cell adhesion and cell cycle 
regulation, and even loss of c-MYC itself [39-41]. An early indicator of the transcriptional 
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repressor role of MYC proteins was the involvement of c-MYC in a negative feedback loop, 
where the introduction of ectopic c-MYC or MYCN was able to downregulate endogenous 
expression of c-MYC in mouse fibroblast cells [42].  Structure and function analyses found 
that the regions of c-MYC that are required for transformation are also required for negative 
autoregulation [43] and led to the idea that the repression of target genes by MYC proteins 
could also contribute to transformation.  
The understanding of transcriptional repression by MYC proteins was greatly advanced via 
the identification of repressed target genes such as transglutaminase-2 (TG2) and interleukin-6 
(IL-6) [44]. Genomic studies have now revealed that MYC proteins repress as many targets 
as they activate, emphasising the role of gene repression by these oncoproteins during 
cellular transformation [14]. One recent example is the identification of TG2 repression by 
MYCN in neuroblastoma, which occurs via the interaction between MYCN with Specificity 
Protein I (SP1) [45]. TG2 is a multifunctional enzyme that catalyses the transamidation and 
multimerisation of proteins, but also promotes programmed cell death and induces neuritic 
differentiation in neuroblastoma cells [46]. Hence downregulation of TG2 by MYCN would 
allow neuroblastoma cells to overcome apoptosis and continue to proliferate. Similarly, 
MYCN has been shown to interact with SP1 to downregulate the expression of MRP3 (also 
known as ABCC3), the gene encoding an intermembrane transporter which is involved in 
the transport of organic anions, prostaglandins, leukotrienes and selected 
chemotherapeutics [47-49]. Another important gene that is downregulated by MYCN is IL-6, 
which has been shown to play an important anti-angiogenic role by inhibiting vascular 
endothelial cell proliferation [50]. The transcriptional repression by MYCN is also supported 
by the interaction between MYC proteins and another transcription factor MIZ-1 (Myc-
interacting zinc finger protein-1) [51]. MIZ-1 is a POZ/BTB (poxvirus and zinc finger/bric-a-
brac, tramtrack and broad complex) domain protein that transactivates genes involved in 
cell cycle regulation as well as tumour suppressor genes via the recruitment of the p300 
histone acetyltransferase [52]. Interestingly, high-level MIZ-1 expression is associated with a 
favourable disease outcome of neuroblastoma [53]. MIZ-1 interacts with the carboxy-
terminal HLH region of c-MYC and MYCN, where the binding of the MYC-MAX 
heterodimer to MIZ-1 disrupts the interaction between MIZ-1 and p300, causing the 
transcriptional repression of tumour suppressor genes [54]. MYC has also been shown to 
recruit a DNA methyltransferase, DNMT3a to the MYC-MIZ-1 complex, suggesting that 
repression can be mediated by the methylation of target gene promoters [55].  
6. Mechanisms of regulating MYCN expression 
Due to the gross transforming ability of deregulated expression of MYC proteins, the 
expression of these protooncogenes is tightly regulated in normal cells at both the 
transcriptional and protein level. For example, MYC mRNA transcripts and proteins have 
very short half-lives and are expressed at constant levels as cells enter the cell cycle [56, 57]. 
Furthermore, anti-proliferative signals trigger rapid down-regulation in expression, and the 
phosphorylation patterns of MYC proteins are known to influence their stability. In addition 
to these mechanisms, expression of MYCN is particularly tightly regulated with regards to 
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timing and tissue specificity. Thus, MYCN is normally expressed during embryonal 
development of the peripheral nervous system in neural crest cells [2]. Neural crest cells 
migrate during mid-gestation to populate the entire peripheral nervous system, including 
autonomic and peripheral ganglia and the adrenal gland. These migrating progenitor cells 
represent a highly proliferative population, and during normal development exit the cell-
cycle and undergo differentiation following the colonisation to the ganglia and spinal cord 
area. This event is orchestrated by extracellular signalling molecules such as mitogens and 
cytokines and coincides with decreased expression of MYCN [56, 58]. Without this strict 
control, dysregulated MYCN expression impairs the ability of progenitor cells to undergo 
differentiation. Studies which sustained MYCN expression in murine neural crest cells 
under the control of a tyrosine hydroxylase promoter, demonstrated the capacity to cause 
neuroblastoma in transgenic mice [3]. Despite this transforming ability, MYCN is vital for 
normal embryonic development, and murine embryos lacking MYCN exhibit profound 
hypoplasia, particularly in the central and peripheral nervous system, disorganized 
architecture of the brain, defective heart development and defects in the lung, genitourinary 
system, stomach, intestines and limb buds [59]. 
In order to understand how extracellular stimuli controlled MYC expression in cells, gene 
mapping studies in association with MYC transcription studies were undertaken, and these 
identified response elements within the MYC transcript as well as their regulators. In 
neuronal cells, MYCN has been shown to be regulated in its promoter region as well as in an 
enhancer region upstream of the coding region. The elongation transcription factor, E2F 
binds to the promoter region of MYCN in response to different mitogenic signals [60]. The 
promoter region also contains positive transcription factor binding sites for SP1, SP3 and 
TGFβ [61]. However, the presence of a retinoic acid response element (RARE) within this 
region allows for negative regulation of MYCN by retinoic acid [62]. 
A key finding was made in 1986 which identified c-MYC as the first eukaryotic gene to be 
negatively regulated by transcriptional elongation control, where a block in the elongation 
of mRNA during transcription occurred during cellular differentiation [63]. This finding 
was later confirmed in MYCN studies where transcription elongation pausing sites were 
identified in exon 1 and intron 1 of human MYCN [64, 65]. Furthermore, there is in vivo 
evidence that the downregulation of MYCN during mouse embryogenesis is partly 
regulated by the control of transcriptional elongation [66]. 
Transcription alone cannot account for the large difference in mRNA levels following the 
introduction of proliferative or anti-proliferative stimuli. The rapid turnover of mRNA was 
also associated with the discovery of two distinct mechanisms of MYC mRNA decay. The 
first involves a translation-independent mechanism involving poly(A) tail shortening of the 
untranslated region of the transcript, while the second represents a translation-dependent 
mechanism that is regulated by a region of mRNA which corresponds to the C-terminus of 
the protein, called the coding region determinant [67-69]. This region is bound to a 75kDa 
protein that protects the region of mRNA from endonuclease attack, in response to growth 
signals that induce c-MYC stabilisation. In the case of MYCN, RNA stability factors have 
also been identified which bind to the untranslated region of MYCN mRNA. In addition, an 
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internal ribosomal entry segment (IRES) in the transcript acts to enhance neuronal specific 
translation [70, 71].  
7. Regulation of MYCN protein expression 
The regulation of MYCN protein levels has also been investigated and phosphopeptide 
analysis has revealed that specific serine and threonine residues of MYCN are 
phosphorylated in vivo. Two residues in particular, Threonine 58 (Thr58) and Serine 62 
(Ser62) have been demonstrated as important determinants of transformation and MYCN 
protein stability and activity [20]. Proliferative stimuli activate phosphorylation of Ser62 by 
cyclin B and Cdk1 during prophase to increase MYCN protein stability [72]. Phospho-ser62 
via a feedback mechanism, then serves as a platform for the phosphorylation of Thr58 by 
glycogen synthase kinase 3 (GSK3), allowing the tumour suppressor FBW7 to bind and 
recruit a ubiquitylation complex, directing MYCN protein for degradation. Mitotic 
degradation of MYCN in the absence of growth factor-dependent signals allows cell cycle 
exit and the commencement of differentiation [73]. Another kinase, Aurora A, has recently 
been identified and shown to inhibit degradation of ubiquitinated MYCN by supporting the 
synthesis of non-degradable ubiquitin chains [74]. 
8. MYCN downstream target genes 
The first transcriptional target for a MYC protein was discovered ten years after the 
identification of human c-MYC. The development of a conditionally expressed c-MYC 
construct, via the fusion of human c-MYC to the hormone-binding domain of the oestrogen 
receptor, led to the identification of a downstream target involved in cell cycle progression, 
α-prothymosin [75]. This approach was then used to identify additional targets including 
ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme involved in polyamine 
synthesis [76]. A different method of identifying MYC targets utilised MYC-null models to 
determine whether the regulation of expression of genes was dependent on the presence of 
a MYC oncogene. Such examples of labour-intensive techniques were invaluable in 
determining single bona fide MYC targets, however recent advances in technology have 
allowed for large-scale analyses of MYC-regulated genes [77, 78].  
Expression microarrays and chromatin immunoprecipitation assays (ChIP) have helped 
researchers identify MYC-regulated targets as well as link MYC-target expression to 
functional cellular pathways which are associated with transformation [79, 80].  MYC and 
MYCN-regulated targets have since been linked to a number of transforming activities 
involving the cell cycle (eg. cyclin D2, CDK4, p21), cell proliferation (e.g. MDM2), growth, 
metabolism (e.g. ribosomal proteins, proteins involved in nucleotide biosynthesis such as 
thymidylate synthase and ODC1), cell adhesion and migration (e.g. integrins) and 
angiogenesis (e.g. thrombospondin) [81-86]. Indeed, the activation and repression of MYC 
target genes is a well-coordinated event. Time course studies using microarray have 
identified differences between early and delayed gene expression responses, following MYC 
activation in a MYC-inducible cell system [87]. Early-response MYC target genes are 
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primarily involved in MAPK signalling, RNA metabolism and transcription factors, which 
suggests a program that prepares cells for entry into the S phase. On the other hand, 
delayed-response MYC target genes are involved in ribosomal biogenesis, nucleotide 
metabolism and energy metabolism, suggesting subsequent maintenance of cells during the 
S phase. Finally, late steady-state MYC-mediated transcription involved genes that regulate 
the cell cycle, nucleotide metabolism and DNA replication. Most genes that were activated 
in the early response were then repressed during this late steady-state phase. Furthermore, 
sustained MYC activation led to the silencing of differentiation-related genes and 
upregulation of genes that are involved cell proliferation. 
During tumorigenesis, MYCN promotes cell cycle progression by the activation of cyclins 
(such as cyclin D1 and D2) as well as cyclin-dependent kinase 4 (CDK4), and represses the 
expression of mediators of cell cycle arrest such as p21 [73]. One important MYCN-
regulated metabolic pathway involves the synthesis of polyamines, which are organic 
cations that enhance transcription, translation and replication [88]. MYCN expression is 
strongly correlated with ODC1 expression in neuroblastoma, and the high levels of ODC1 
expression that are driven by MYCN-amplification and over-expression are strongly 
associated with poor clinical outcome of this disease [89].  
Another gene whose expression is strongly correlated with MYCN expression in 
neuroblastoma is that encoding the multidrug resistance-associated protein, MRP1, a 
glycoprotein that belongs to the superfamily of ATP-binding cassette (ABC) transmembrane 
transporters [90-92]. MRP1, also known as ABCC1, is able to confer resistance to a broad 
range of structurally unrelated chemotherapeutic drugs [93]. MRP1 has since been shown to 
be a downstream transcriptional target of MYCN in neuroblastoma, whose expression is 
highly predictive of outcome in this disease [91, 94, 95]. The expression of another gene that 
is also a member of the ABC family of transporters, MRP4 (or ABCC4), has also been 
demonstrated to be positively correlated to MYCN expression in neuroblastoma and like 
MRP1, its over-expression is a prognostic indicator of neuroblastoma outcome [95, 96]. In 
fact, it has recently been shown that MYCN can coordinate the transcription of a large set of 
ABC genes, and the expression profiles of these genes correlate with MYCN function [48]. 
9. MYCN tumorigenesis 
The evidence for a clinical role of MYCN in the tumorigenesis of neuroblastoma was first 
recognised when the amplification of the MYCN oncogene was identified in 24 out of 63 
primary untreated neuroblastoma tumour samples and appeared to correlate with more 
advanced stage of disease [97]. MYCN-amplification was subsequently associated with 
rapid disease progression as well as poor patient outcome in this disease [98]. Importantly, 
the progression-free survival of neuroblastoma patients was then shown to be dose-
dependent on MYCN where higher copy number resulted in lower survival. This association 
was independent of patient age and disease stage. MYCN-amplification was later confirmed 
in numerous studies to be a powerful prognostic marker for predicting neuroblastoma 
patient outcome, independent of other clinical variables [99-102]. Determination of MYCN 
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amplification status is now routinely determined in primary neuroblastomas and is one of 
the most powerful prognostic markers yet identified for this disease. 
The MYCN oncogene is normally located on the distal short arm of chromosome 2 (2p24). 
This region was found to be amplified across a panel of neuroblastoma cell lines [8], and 
although the exact mechanism by which this occurs is unknown, the process of 
amplification usually results in 50 to 400 copies of the gene per cell, leading to the 
production of abnormally high levels of MYCN RNA and protein, presumably conferring a 
selective advantage to the tumour cell [103].  
The potent transforming ability of MYCN has been demonstrated by several studies, while 
MYCN transfection studies have demonstrated that the oncoprotein plays a crucial role in 
neuroblastoma progression [104, 105]. Conditional overexpression of MYCN in 
neuroblastoma cell lines was shown to dramatically increase the growth rates and metastatic 
ability of these tumour cells, increase DNA synthesis, and inhibit exit from the cell cycle and 
neuronal differentiation [106, 107]. Furthermore, targeted expression of the MYCN oncogene 
in neuroectodermal cells of transgenic mice resulted in the development of neuroblastoma 
[3]. In these animals, human MYCN (hMYCN) oncogene expression was targeted to neural 
crest cells via an upstream rat tyrosine hydroxylase promoter. Tyrosine hydroxylase is the 
first and rate-limiting step in catecholamine synthesis. In contrast, reduction in the MYCN 
RNA levels via introduction of MYCN antisense oligonucleotides in vitro as well as in vivo 
led to reduced rates of growth and of tumorigenicity [4, 108, 109].  
Whilst MYCN-amplification has been shown to be associated with a highly malignant 
neuroblastoma phenotype, the precise role of this oncogene in non-amplified tumours 
remains controversial. Approximately 40% of those neuroblastomas that lack MYCN-
amplification are nevertheless still clinically aggressive, and the clinical significance of 
MYCN expression in the absence of MYCN-amplification, remains elusive with evidence 
both for and against an association with adverse outcome [110, 111]. One study that 
analysed both MYCN mRNA and protein levels in a cohort of non-amplified tumours, 
found no prognostic significance attributable to expression of this oncogene [110]. Rather, 
since the survival rates for older children with or without high MYCN expression were 
poor, the results suggested that additional factors contribute to tumour aggressiveness in 
this subgroup. Furthermore, in a more recent study involving 91 neuroblastoma patients, 
high MYCN expression was found to be associated with a favourable outcome in 
neuroblastomas lacking MYCN-amplification [111]. Interestingly, in this study, the forced 
expression of MYCN significantly suppressed growth of non-amplified neuroblastoma cells 
by inducing apoptosis. It is possible that the prognostic value of MYCN gene expression in 
neuroblastoma may be an artefact of the different biology of neuroblastoma in infants 
compared to older children, and further well-controlled, large cohort studies will be needed 
in order to clarify the precise role of MYCN in non-amplified neuroblastoma. 
Although the majority of the literature investigating MYCN in cancer comes from studies on 
neuroblastoma, this oncogene has also been shown to play a role in the tumorigenesis of 
other cancers, both adult and paediatric. For example, MYCN amplification and/or over-
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expression has been observed in high grade C5 serous ovarian tumours, small cell lung 
cancer, rhabdomyosarcoma and neuroendocrine prostate cancer  [112-115], while gain of 2p 
(and MYCN) plays a role in chronic lymphocytic leukaemia [116]. In childhood 
medulloblastoma, MYCN, c-MYC, and to a lesser extent MYCL, appear to be involved in the 
biology of this disease [117]. MYCN amplification occurs in up to 10% of medulloblastoma 
patients and is associated with poor clinical outcome, and like neuroblastoma, the risk of 
death increases with increasing copy number [117]. Furthermore, MYCN expression was 
found to be high in foetal cerebella, with the levels decreasing to almost absent in adult 
cerebella, suggesting that MYCN is essential to normal foetal development [118]. 
Interestingly, in this study, MYCN expression was absent from the medulloblastoma cell 
lines tested, which differed from the expression pattern observed in the primary tumours 
[118]. Finally, as with neuroblastoma, the association of MYCN mRNA levels with clinical 
outcome remains unclear [119] and it has been postulated that mRNA levels of both c-MYC 
and MYCN may only be clinically relevant in subgroups of medulloblastoma [117]. 
The most compelling evidence for a role of MYCN in the biology of medulloblastoma comes 
from two mouse models of this disease. Firstly, targeted expression of MYCN to the 
cerebellum in transgenic mice has demonstrated the importance of MYCN in contributing to 
the initiation and progression of medulloblastoma and also in the metastatic spread of 
disease to the spinal and paraspinal tissues via cerebral spinal fluid. Furthermore, the 
MYCN downstream targets Odc1, MDM2 and Fb1 were upregulated and correlated with 
MYCN mRNA levels [118].  The second model used targeted Smoothened (SmoA1) to the 
cerebella of transgenic mice, which were then crossed with mice harbouring conditional 
knock-out of MYCN, to demonstrate that MYCN was essential for medulloblastoma 
tumorigenesis [120]. These two models thus serve to demonstrate the importance of MYCN 
in the initiation and progression of this disease. 
10. Molecular targeting of MYCN for therapeutic benefit 
Molecular targeted therapy involves targeting malignant cell growth by directly inhibiting 
the function of specific molecules within a cell, namely those that are responsible for driving 
cancer progression. Such agents aim to block or exploit various aspects of cancer biology, 
such as genetic instability, proliferative signal transduction, aberrant cell cycle control, 
deregulated survival, angiogenesis and metastasis [121]. Numerous methods of molecular 
targeted therapy have been investigated, including antisense oligonucleotides (ASOs) that 
hybridise to and inhibit the mRNA of a specific gene; peptide nucleic acids (PNAs), which 
are DNA analogues that specifically hybridise to DNA and/or RNA in a complementary 
manner to inhibit transcription/translation of a target gene; and small interfering RNA 
(siRNA), which silences gene expression by inducing the sequence specific degradation of 
complementary mRNA or by inhibiting translation [122]. However, such technologies 
although useful in the laboratory, have had limited success in the clinic due to problems 
associated with their delivery.  
Immunotherapy has also generated interest, and utilises the body’s immune system to target 
and remove cancer cells by the recognition of certain molecular markers, or block specific 
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cell receptor pathways. Another approach to molecular targeting, involves the development 
of synthetic small molecule inhibitors which potentially have the ability to interfere with a 
molecular target at multiple levels [122]. These small molecules may diffuse into cells to act 
directly on intracellular targets, such as inhibiting the expression of a target gene at the 
transcriptional or translational level, or inhibiting the function of a protein by directly 
binding to the protein and inducing conformational changes that prevent its interaction with 
other factors [123]. Synthetic small molecules are generally defined by a molecular weight 
cut-off of <500Da. They are favoured by the pharmaceutical industry because of their 
attractive pharmacokinetic properties, especially tumour cell penetration, and their relative 
ease of development and pharmaceutical production [123]. At present, strategies to develop 
novel small molecule inhibitors as viable therapies are aimed at using these technologies in 
combination with other cytotoxic drugs, with the hope of reducing drug dosages, and thus 
overcoming drug resistance associated with intensive chemotherapy, and reducing drug-
related toxicity and side effects.  
A number of molecular mechanisms have been identified as possible targets for the 
treatment of neuroblastoma. However, the prominent deregulated expression and 
amplification of MYCN suggests that this oncogene represents an ideal target for therapeutic 
inhibition [124]. In addition, normal MYCN expression is restricted to the early stages of 
embryonic development and is virtually undetectable in normal post-natal tissues, therefore 
weighing in its favour as a target for inhibition. Inhibition of MYCN expression by antisense 
treatment against MYCN mRNA or by retinoic acid has been demonstrated to decrease 
proliferation and induce neuronal differentiation in neuroblastoma cells [125-127]. 
Furthermore, the introduction of MYCN antisense oligonucleotides in the human MYCN 
(hMYCN) trangenic mouse model led to reduced rates of tumour growth in these animals [4, 
108, 109].  
Inhibition of MYCN protein through its protein-protein interactions and protein-DNA 
interactions was previously seen as too difficult to target by small molecules [128]. 
However, it has been reported that small-molecule antagonists of MYC/MAX dimerisation 
interfered with c-MYC-induced oncogenic transformation of chicken embryo fibroblasts in 
vitro [129]. In addition, a number of endogenous MYCN/MAX antagonists such as 
MAX/MAX have been found to compete for binding to E-box sequences and repress 
transcription [130], causing cell cycle arrest, terminal differentiation or apoptosis. More 
recently, inhibition of c-MYC transcription via a Bromodomain and Extra Terminal Domain 
(BET) inhibitor, JQ1, has been described [131]. This inhibitor has been shown to disrupt c-
MYC mRNA synthesis by preventing the recruitment of coactivator proteins required for c-
MYC transcriptional initiation and mRNA elongation [131]. Furthermore, this molecule was 
able to decrease the tumour burden in an orthotopic mouse model of multiple myeloma. 
Treatment of several MYCN-amplified neuroblastoma cell lines with JQ1, resulted in a 
decrease in MYCN expression, although this effect was far less dramatic that that observed 
in a c-MYC driven cell line [132]. Despite promising evidence for targeting MYCN as a 
therapeutic strategy, no MYC or MYCN inhibitors have yet entered clinical trial, and further 
studies are required to develop effective MYCN inhibitors. 
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11. Future perspectives 
The validity for targeting MYCN for therapeutic benefit relies on the gross transforming 
ability of this transcription factor. MYCN represents a particularly attractive target due to its 
lack of expression in adult and normal paediatric tissues. Although MYCN, and MYC 
proteins in general are commonly viewed as “undruggable” due to the nature of these 
proteins, MYCN offers potential advantages at a number of levels for therapeutic inhibition, 
either upstream, or downstream along the MYCN transcriptional pathway. If clinically 
useful MYCN inhibitors can be successfully developed, they are likely to find application in 
combination therapies involving conventional chemotherapeutic drugs and be used as an 
improved approach to target aggressive cancers that are driven by this oncoprotein. 
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